A MARKET IN EVOLUTION
The average life expectancy continues to rise in Europe, and with it an increase in the number of patients requiring nursing care.
The third health programme promoted by the EU calls for chronic disease management with the least possible impact on people's lives.
The new dehospitalisation policies promoted by the SSN result in the home management of treatment, with the dual benefit of reducing overhead costs on the one hand, and easing the impact on the patient's life on the other.
A win-win solution to ensure not only the quality of life of the patient, but also, the correct implementation of treatment protocols entails the direct management of the same treatments by the pharmaceutical companies.
Dedicare offers pharmaceutical companies a portfolio of advanced services for the direct management of treatments.
DEDICARE: QUALITY IN CARING
Therapy effectiveness is related to several factors, the crucial points being: patient information, presence of caregivers, following the correct protocol of the treatment and its ease of access and management.
Therapy at home can improve its effectiveness: it is less strain on the patient and presents the nurse as a new reference point for information, advice and necessary instructions to help cope with the illness in a more serene and knowing way.
The nurse becomes a crucial link between the pharmaceutical company and the patient: he / she administers treatment, assures adherence to protocol, monitors feedback, collects information and communicates with the patient.
Dedicare makes this development possible because it relies on an extensive network of certified and qualified nurses throughout the entire country, so as to ensure continuity in the nurse-patient relationship.
THE CHALLENGE FOR HEALTHCARE COPING WITH
EUROPEAN DEMOGRAPHIC CHANGE
148 MILIONI DI
62,4 MILIONI DI
25% DELLA VITA SPESO IN MALATTIA